You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

 

Online download statistics by month:

Online download statistics by month: August 2021 to March 2024

AbstractFullPdf
Aug 2021654655282
Sep 2021260261131
Oct 202121521587
Nov 202117617767
Dec 202114014049
Jan 202214614983
Feb 202213814675
Mar 202216216499
Apr 202218118366
May 202212412967
Jun 202211712255
Jul 202214414845
Aug 202212913155
Sep 202215215564
Oct 202217217863
Nov 202214614866
Dec 202210911248
Jan 202312412548
Feb 202314314350
Mar 202314815373
Apr 2023757538
May 2023889135
Jun 202310310436
Jul 2023798231
Aug 2023686827
Sep 2023777731
Oct 2023939346
Nov 2023899030
Dec 202311111149
Jan 202410210366
Feb 2024828346
Mar 202410710751
Total465447182059